# US 2025/0152503 A1 · Implantable devices for the sustained delivery of an opioid antagonist and methods for treating inflammatory, neuroinflammatory and metabolic disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152503 A1
- Document ID: US20250152503A1
- Status: Published application
- Kind: A1
- Application number: 18/840,456
- Filed: 2023-02-21
- Published: 2025-05-15
- Earliest claimed: 2022-02-22
- Assignees: Delpor, Inc.
- Applicants: Delpor, Inc.
- Inventors: Gregory A. Watkins
- Web page: https://patentgrep.com/patent/US20250152503A1

## CPC

- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/20: Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2072: {characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms (A61K9/0004, A61K9/0056, A61K9/0065 take precedence)}
- A61K 9/2095: {Tabletting processes}
- A61K 31/343: condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
- A61K 31/485: Morphinan derivatives, e.g. morphine, codeine
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Diffusion-based, implantable devices for the delivery of an opioid antagonist, such as naltrexone, are described. The devices are cylindrical or discoidal in shape and fitted with a biocompatible membrane. These are filled with a compressed formulation of the opioid antagonist, and optionally, a binder. Upon introduction of an aqueous fluid into the device, the compressed formulation erodes at a constant rate along one axis to release the opioid antagonist from the device at a constant rate. The rate is selected to range from approximately 0.02-2.00 mg/day for the treatment of inflammatory, neuroinflammatory, or metabolic disorders.

## Claims

### Claim 1

A device for delivery of an opioid antagonist, comprising:
a device comprising an interior reservoir with an inner diameter, a first end, a second end, and a porous partition, the device dimensioned for subcutaneous implantation into a subject;
a solid formulation comprising an opioid antagonist and one or more of a binder, a stabilizing excipient, and a lubricant, the solid formulation in the form of a compressed shape with a diameter equal to or greater than 80% of the inner diameter of the interior reservoir,
wherein the compressed shape when hydrated forms an aqueous phase in the interior reservoir of the device, the aqueous phase comprising dissolved opioid antagonist that is released from the device by diffusion across the porous partition for a period of at least about one month.

### Claim at position 2

2-4. (canceled)

### Claim 5 (depends on 1)

The device of claim 1, wherein the compressed shape is selected from a tablet, a pellet and a rod.

### Claim 6 (depends on 5)

The device of claim 5, wherein the compressed shape has a diameter equal to or greater than 90% of the inner diameter of the interior reservoir.

### Claim 7 (depends on 1)

The device of claim 1, wherein the solid formulation comprises a binder.

### Claim 8 (depends on 7)

The device of claim 7, where the binder is selected from the group consisting of lactose, maltose, mannitol, trehalose, hydroxypropylcellulose, polyvinylpyrrolidone, polyethyleneglycol, a fatty acid or alcohol containing a minimum of 12 carbon atoms, and a dicarboxylic acid containing a minimum of 8 carbon atoms.

### Claim 9

(canceled)

### Claim 10 (depends on 9)

The device of claim 9, wherein the solid formulation comprises a stabilizing excipient selected from a metal chelating agent, a buffering agent, and an antioxidant.

### Claim 11 (depends on 1)

The device of claim 1, wherein the solid formulation has a melting point greater or equal to about 40° C.

### Claim at position 10

12-20. (canceled)

### Claim 21 (depends on 1)

The device of claim 1, wherein the opioid antagonist is naltrexone base or a pharmaceutically acceptable salt of naltrexone.

### Claim at position 12

22-25. (canceled)

### Claim 26 (depends on 1)

The device of claim 1, wherein the opioid antagonist is in amount to maintain a therapeutically effective plasma level of the opioid antagonist and/or a metabolite thereof for the period.

### Claim at position 14

27-28. (canceled)

### Claim 29 (depends on 1)

A method for in vivo delivery of an opioid antagonist, comprising:
providing a device according to claim 1, and
implanting the device into a subcutaneous space of a human subject, whereby said implanting results in an aqueous fluid in the subcutaneous space entering the device to hydrate the formulation, or
prior to implanting the device into a subcutaneous space of a human subject, contacting the device with an aqueous fluid to wet the device membranes and formulation.

### Claim at position 16

30-32. (canceled)

### Claim 33 (depends on 1)

A method for the treatment of an inflammatory, neuroinflammatory, or metabolic disorder, comprising:
providing a device according to claim 1,
administering the device to a human subject by subcutaneous implantation, whereby said administering provides delivery of the opioid antagonist in an amount that provides a therapeutic blood level for a period of between about 1-36 months.

### Claim at position 18

34-38. (canceled)

### Claim 39 (depends on 10)

The device of claim 10, wherein the metal chelating agent is ethylenediaminetetraacetic acid.

### Claim 40 (depends on 10)

The device of claim 10, wherein the buffering agent is selected from the group consisting of a phosphate salt, a carboxylate salt, and an amino acid.

### Claim 41 (depends on 10)

The device of claim 10, wherein the antioxidant is selected from ascorbic acid, an ascorbic acid ester, tocopherol, a tocopherol ester, cysteine, a cysteine ester or amide, methionine, a methionine ester or amide, butylated hydroxytoluene (BHT) and butylated hydroxyanisole (BHA).

### Claim 42 (depends on 1)

The device of claim 1, wherein the solid formulation comprises a lubricant selected from the group consisting of stearic acid, magnesium stearate, stearin, calcium stearate, sodium lauryl sulfate, glyceryl behenate, sodium benzoate, and talc.
